GLUEMonte Rosa Therapeutics, Inc.
What is the market doing?
The market is leaning against it: in a downtrend (−42% vs 200-day) and a crowded short (+19% of shares).
In a downtrend, below its 50- and 200-day averages. Oversold (RSI 26). Price is −42% vs its 200-day average.
Insiders were net sellers over the 90 days ending Oct 8, 2026; selling is often routine (taxes, diversification).
A crowded short, settled Sep 15, 2026, more than a week of normal trading to cover, a crowded exit.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. Insider selling is often routine (taxes, diversification); only cluster buying is a strong tell.
How GLUE is trading
Monte Rosa Therapeutics, Inc. is +63% over the past year while the S&P 500 is +18%: 45 points ahead of the market.
1-year return · S&P 500 +18%
- vs 200-day average
- −42%
vs 200-day average · a clear downtrend
- RSI (14)
- 26
RSI (14) · oversold, sold harder than it has been bought
- Below its 52-week high
- 59%
Below its 52-week high
Details›
- Last close2026-10-09
- $10.32
- 1 monthS&P 500 +2.7%
- −28%
- 1 yearS&P 500 +18%
- +63%
- 5 yearsS&P 500 +88%
- −67%
- vs 50-day average$13.87
- −26%
- 52-week high
- $25.31
- 52-week low
- $6.33
- Annualised volatility
- 108%
- Insider buying, net, 6 monthsForms 3/4/5 to 2026-10-08
- −$876K
| Year | Return |
|---|---|
| 2026 (year to date) | −34% |
| 2025 | +126% |
| 2024 | +23% |
| 2023 | −26% |
| 2022 | −63% |
| Month | Years | Positive | Average |
|---|---|---|---|
| Jan | 5 | 1 of 5 | −4.0% |
| Feb | 5 | 2 of 5 | −3.2% |
| Mar | 5 | 2 of 5 | +2.9% |
| Apr | 5 | 2 of 5 | −13% |
| May | 5 | 2 of 5 | −0.19% |
| Jun | 5 | 3 of 5 | +5.3% |
| Jul | 6 | 5 of 6 | +6.2% |
| Aug | 6 | 2 of 6 | +2.1% |
| Sep | 6 | 2 of 6 | −4.5% |
| Oct | 6 | 4 of 6 | +18% |
| Nov | 5 | 2 of 5 | +2.8% |
| Dec | 5 | 2 of 5 | +8.3% |
End-of-day closes from IEX; the S&P 500 comparison uses SPY over the same window. Prices are a reference point, not a basis for trading decisions.